Evidence map›Paper›PMID 32016503›Full record

ArticleCancer immunology, immunotherapy : CII2020

Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.

Brian W Simons, Fabiana Cannella, Dayana T Rowley, Raphael P Viscidi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Virus-like Particles for TEM Regulation and Antitumor Therapy.Journal of functional biomaterials · 2022
    Review
  5. Novel Tumor-Targeting Nanoparticles for Cancer Treatment-A Review.International journal of molecular sciences · 2022
    Review
  6. Review
  7. The contribution of bovines to human health against viral infections.Environmental science and pollution research international · 2021
    Review
  8. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brian W SimonsDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Fabiana CannellaThe Department of Pediatrics, Johns Hopkins University, 600 North Wolfe Street, Blalock Building 1153, Baltimore, MD, 21287, USA.
Dayana T RowleyThe Department of Pediatrics, Johns Hopkins University, 600 North Wolfe Street, Blalock Building 1153, Baltimore, MD, 21287, USA.
Raphael P ViscidiThe Department of Pediatrics, Johns Hopkins University, 600 North Wolfe Street, Blalock Building 1153, Baltimore, MD, 21287, USA. rviscid1@jhmi.edu.ORCID http://orcid.org/0000-0002-7906-8002

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is a candidate for immunotherapy because cancer cells express tissue-specific proteins that can be therapeutic targets. However, immune checkpoint inhibitors and active immunization have performed poorly in clinical trials. We developed a novel virus-like particle (VLP) vaccine composed of bovine papillomavirus L1 protein engineered to display surface docking sites. We decorated VLPs with peptides encoding T cell epitopes from two prostate cancer-associated tumor antigens, prostate stem cell antigen (PSCA), and prostatic acid phosphatase (PAP-1 and PAP-2), and a neo-antigen, stimulator of prostatic adenocarcinoma-specific T cells (SPAS-1). The VLP vaccines induced a mean frequency of antigen-specific IFN-γ secreting CD8 + T cells of 2.9% to PSCA, 9.5% to SPAS-1, 0.03% to PAP-1, and 0.03% to PAP-2 in tumor-bearing TRAMP mice. We treated TRAMP mice at 19-20 weeks of age, when mice have advanced stages of carcinogenesis, with either VLP vaccine, anti-PD1 antibody, or combination immunotherapy. The VLP vaccine alone or in combination with anti-PD1 antibody significantly reduced tumor burden, while anti-PD1 antibody had a modest non-significant therapeutic effect. All treatments significantly increased CD3 + and CD8 + T cell infiltration into tumor tissue compared to control mice, and combination therapy resulted in significantly greater CD3 + and CD8 + T cell infiltration than monotherapy. Reduction in tumor burden in vaccine-treated mice was inversely correlated with CD8 + T cell numbers in tumor tissue. No other immunotherapy has shown efficacy in this animal model of advanced prostate cancer, making bovine papillomavirus VLPs an attractive vaccine technology to test in patients with metastatic prostate cancer.

Indexed as

Acid PhosphataseAnimalsAntigens, NeoplasmCancer VaccinesCapsid ProteinsCD8-Positive T-LymphocytesDisease Models, AnimalEpitopes, T-LymphocyteGPI-Linked ProteinsHumansInterferon-gammaMaleMice, TransgenicNeoplasm ProteinsProstate-Specific AntigenProstatic NeoplasmsAcid PhosphataseAntigens, NeoplasmCancer VaccinesCapsid ProteinsEpitopes, T-LymphocyteGPI-Linked ProteinsInterferon-gammaL1 protein, Bovine papillomavirusNeoplasm ProteinsProstate-Specific Antigenprostatic acid phosphatasePSCA protein, humanVaccines, Virus-Like ParticleAntigen-specific CD8 + T cellsBovine papillomavirusImmune checkpoint inhibitorProstate cancerTRAMP miceVLP vaccine

Identifiers

PMID32016503
PMCPMC11027804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.